Health Trials

Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype

ConditionsOvarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-100
SponsorNordic Society of Gynaecological Oncology - Clinical Trials Unit

About this trial

This is a prospective observational multi-country, multi-center study of a large real-world cohort of first line (1L) epithelial ovarian cancer patients, exposed to standard of care (SOC) treatment stratified according to BRCA1/2 and HRD status.

Eligibility criteria

Qualifiers

FIGO stage I-II with a known BRCA1/2 mutation (germline/gBRCA or somatic/tBRCA)

FIGO stage III-IV of any histology

Women aged ≥18 years of age at the time of diagnosis

Patients intended for platinum-based chemotherapy treatment

Disqualifiers

Non-epithelial ovarian cancer, borderline tumors, or mucinous histology

Patients with FIGO stage I-II, BRCAwt ovarian cancer

Trial design

Treatments tested in this trial

  • Standard of care

Treatment groups

1,000 Participants
are divided into 1 treatment group

Locations

1

Map coordinates are unavailable for these locations. Locations are shown below instead.

RigshospitaletRecruiting2100, København Ø, Region SjællandDenmarkDenmark

Sponsors and collaborators

Nordic Society of Gynaecological Oncology - Clinical Trials Unit

Lead sponsor

Source ClinicalTrials.gov